Clinical safety of neostigmine or sugammadex to reverse rocuronium-induced neuromuscular blockRokuronilla aikaansaadun lihasrelaksaation kumoaminen neostigmiinilla tai sugammadeksilla: kliininen turvallisuus

Klaus Olkkola0 个研究点目标入组 50 人开始时间: 2009年6月24日最近更新: 2014年10月27日

适应症

试验速览

暂无简介。

•1.Male or female subjects belonging to ASA class 1-4.
•2.Admitted to hospital for surgical procedures with an estimated at least 30 min duration of general anaesthesia.
•3.Informed written consent for participation in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Patients with muscular dystrophies, myopathy or cerebral palsy.
•2.A previous history of intolerance to the study drugs or to related compounds and additives.
•3.Clinically significant renal or hepatic dysfunction.
•4.Marked ventilatory impairment due to underlying respiratory disease.
•5.Raised intracranial pressure.
•6.Patients younger than 18 and older than 70 years.
•7.Body mass index greater than 32.5 (Appendix 1).
•8.Patients on concomitant medication known to significantly affect the neuromuscular transmission.
•9.Pregnancy or lactation. Pregnancy and lactation will be excluded by anamnestic information.
•10.Participation in any other studies involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study.

发起方

Klaus Olkkola